LONDON (Reuters) - AstraZeneca said on Thursday it had struck four research collaborations in the hot area of genome editing as it bets on a new technology to deliver better and more precise drugs for a range of diseases. The academic and commercial tie-ups will allow AstraZeneca to use so-called CRISPR technology across its entire drug discovery platform in areas such as oncology, cardiovascular, respiratory and immune system medicine. (Reporting by Ben Hirschler; Editing by David Holmes)
via Health News Headlines - Yahoo News Read More Here..
No comments:
Post a Comment